Evolus Loaded Up On Jeuveau Ahead Of A Tariff It Now Expects To Dodge, Adding $62.8 Million In Payables
Inventories rose $55.8 million since year-end as Evolus pulled forward Jeuveau purchases, with Daewoong payments deferred.
Evolus, which sells injectable aesthetic products to licensed practitioners, raised inventories by $55.8 million and accounts payable by $62.8 million between December 31, 2025 and September 30, 2026, a build the company attributes mainly to accelerated Jeuveau purchases. Commerce guidance in September now leads it to expect that Jeuveau will not face the Section 232 tariff the purchases were meant to beat, its quarterly report says.
Buying ahead of a tariff
Other current assets rose $8.4 million over the same stretch. The company said it pulled forward Jeuveau inventory and samples under a deferred payment arrangement because of uncertainty over tariffs on patented pharmaceuticals imported from South Korea, where Daewoong makes the toxin.
The prior quarter's filing put the pull-forward effect at $17.6 million for inventory and payables as of June 30 and flagged a possible 15% tariff on Jeuveau. Now the company says it "currently do not expect Jeuveau® to be subject to such tariffs," while cautioning that tariff policy and guidance remain subject to change.
Evolysse, the hyaluronic acid gel line imported from the European Union, still faces a 10% tariff under Section 301, the filing says.
Deferred payments to Daewoong
Under the agreed terms with Daewoong, payments for the accelerated purchases are generally pushed to the periods when the inventory would otherwise have been bought under the original demand forecast. The company estimates related cash outflows will stay generally aligned with that forecast.
In the earnings release, Evolus said it now holds 12 months of inventory and that cash use will not be affected by the pull-forward. Balance sheet inventories stood at $82.8 million at September 30, against $27.0 million at year-end.
A thin cushion
Cash and equivalents ended September at $41.7 million, down from $53.8 million at year-end. Accounts payable and accrued expenses totaled $122.8 million in the release. Stockholders' deficit was $37.8 million, and outstanding debt principal was $160.0 million, due in 2029 and 2030.
Third-quarter revenue rose 13.0% to $78.0 million, and net loss narrowed to $12.5 million. The company reaffirmed its full-year 2026 revenue guidance of $330 million to $337 million and a low- to mid-single digit adjusted EBITDA margin. It also disclosed an October option agreement on a hair-regrowth injectable, with $1.5 million of option consideration and a $7.5 million upfront payment if exercised.
The company says it expects to fund the option payments from existing liquidity, and the deferred Daewoong payments are meant to land when the inventory would otherwise have been bought.
Sources
- 10-Q Filing — Evolus (EOLS) — SEC EDGAR
- 10-Q Filing — Evolus (EOLS), Q2 FY2026 filed 2026-08-05 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, q32026eolsex991.htm) — Evolus, filed 2026-11-04 — SEC EDGAR
- Evolus GAAP EPS of -$0.19 misses by $0.02, revenue of $77.9M beats by $0.32M (EOLS:NASDAQ) | Seeking Alpha — seekingalpha.com
- Evolus to Report Third Quarter Financial Results on November 4, 2026 – Company Announcement - FT.com — Financial Times
- Evolus Q3 2026 Earnings Call Transcript — benzinga.com
- Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook — businesswire.com
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On — globenewswire.com